
    
      Phase 1, multi-center, open-label, dose-escalation study to:

        -  Evaluate the safety profile and MTD of RP-6306 when administered orally to establish the
           recommended Phase 2 dose and schedule

        -  Characterize the PK and pharmacodynamics of RP-6306 monotherapy

        -  Assess preliminary anti-tumor activity associated with RP-6306 monotherapy
    
  